Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.11.4395

Endpoint of Cancer Treatment: Targeted Therapies  

Topcul, Mehmet (Department of Biology, Faculty of Science, Istanbul University)
Cetin, Idil (Department of Radiobiology, Institute of Science, Istanbul University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.11, 2014 , pp. 4395-4403 More about this Journal
Abstract
Nowadays there are several limitations in cancer treatment. One of these is the use of conventional medicines which not only target cancer cells and thus also cause high toxicity precluding effective treatment. Recent elucidation of mechanisms that cause cancer has led to discovery of novel key molecules and pathways which have have become successful targets for the treatments that eliminate only cancer cells. These so-called targeted therapies offer new hope for millions of cancer patients, as briefly reveiwed here focusing on different types of agents, like PARP, CDK, tyrosine kinase, farnysyl transferase and proteasome inhibitors, monoclonal antibodies and antiangiogenic agents.
Keywords
Cancer; cytotoxic chemotherapy; targeted therapy;
Citations & Related Records
Times Cited By KSCI : 8  (Citation Analysis)
연도 인용수 순위
1 O'Regan RM, Khuri FR (2004). Farnesyl transferase inhibitors: the next targeted therapies for breast cancer? Endocrin Relat Cancer, 11, 191-205.   DOI
2 Papeo G, Casale E, Montagnoli A, Cirla A (2013). PARP inhibitors in cancer therapy: an update. Expert Opinion on Therapeutic Patents, 23, 503-14.   DOI
3 Pardee AB (2009). What goes wrong in cancer. In 'The biology and treatment of cancer', Eds. Pardee AB, Stein GS. John Wiley & Sons, Inc, New Jersey, pp 3-19.
4 Paul MK, Mukhopadhyay AK (2004). Tyrosine kinase-role and significance in cancer. Int J Med Sci, 1, 101-15.
5 Pearson M, Garcia-Echeverria C, Fabbro D (2006). Protein tyrosine kinases as targets for cancer and other indications. In 'Protein tyrosine kinases', Eds. Fabbro D, Mc Cormick F. Humana Press Inc, Totowa, New Jersey, pp 1-29.
6 Pitot HC, Loeb DD (2002). Some basic and applied principles of cancer chemotherapy. In 'Fundamentals of Oncology', Eds. Pitot HC, Loeb DD. Marcel Dekker Inc, New York, pp 901-945.
7 Popovic R, Licht JD (2012). Emerging epigenetic targets and therapies in cancer medicine. Cancer Discov, 2, 405-13.   DOI
8 Rayburn ER, Zhang R (2008). Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible? Drug Discov Today, 13, 513-21.   DOI   ScienceOn
9 Populo H, Lopes JM, Soares P (2012). The mTOR signalling pathway in human cancer. Int J Mol Sci, 13, 1886-918.   DOI
10 Rajkumar SV, Richardson PG, Hideshima T, Anderson KC (2005). Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol, 23, 630-9.
11 Ren R (2005). Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer, 5, 172-83.   DOI
12 Reya T, Morrison SJ, Clarke MF, Weissman IL (2001). Stem cells, cancer, and cancer stem cells. Nature, 414, 105-11.   DOI   ScienceOn
13 Rowinsky EK, Windle JJ, Von Hoff DD (1999). Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol, 17, 3631-52.
14 Roy R, Yang J, Moses MA (2009). Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol, 27, 5287-97.   DOI   ScienceOn
15 Satpute PS, Hazarey V, Ahmed R, Yadav L (2013). Cancer stem cells in head and neck squamous cell carcinoma: a review. Asian Pac J Cancer Prev, 14, 5579-87.   과학기술학회마을   DOI
16 Sawyers C (2004). Targeted cancer therapy. Nature, 432, 294-7.   DOI   ScienceOn
17 Schwartz GK, Shah MA (2005). Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol, 23, 9408-21.   DOI   ScienceOn
18 Scott AM, Allison JP, Wolchok JD (2012). Monoclonal antibodies in cancer therapy. Cancer Immun, 14, 1-8.
19 Shchemelinin L, Sefc EN (2006). Protein kinases, their function and implication in cancer and other diseases. Folia Biologica (Praha), 52, 81-100.
20 Sell S (2006). Potential gene therapy strategies for cancer stem cells. Curr Gene Ther, 6, 579-91.   DOI
21 Sell S (2009). Stem cells and cancer: An introduction. In 'Stem cells and cancer', Ed. Majumder S. Springer, USA, pp 1-31.
22 Sharova NP (2005). How does a cell repair damaged DNA? Biochemistry, 70, 275-91.
23 Sotgia F, Martinez-Outschoorn UE, Pavlides S, et al (2011). Understanding the warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment. Breast Cancer Res, 13, 213-26.   DOI
24 Sridhar SS, Hedley D, Siu LL (2005). Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther, 4, 677-85.   DOI   ScienceOn
25 Sun QC, Liu MB, Shen HJ, et al (2013). Inhibition by imatinib of expression of O-glycan-related glycosyltransferases and tumor-associated carbohydrate antigens in the K562 human leukemia cell line. Asian Pac J Cancer Prev, 14, 2447-51.   과학기술학회마을   DOI
26 Suter R, Marcum JA (2007). The molecular genetics of breast cancer and targeted therapy. Biologics, 1, 241-58.
27 Tew KD, Gate L (2001). Glutathione S-transferases as emerging therapeutic targets. Expert Opinion on Therapeutic Targets, 5, 477-89.   DOI
28 Turella P, Cerella C, Filomeni G, et al, (2005) Proapoptotic activity of new glutathione S-transferase inhibitors. Cancer Res, 65, 3751-61.   DOI
29 Wright D (2007). Cytotoxic chemotherapy. In 'The biology of cancer', Ed. Gabriel JN. John Wiley& Sons Ltd, England, pp 45-53.
30 Vendetti FP, Rudin CM (2013). Epigenetic therapy in non-small-cell lung cancer: targeting DNA methyltransferases and histone deacetylases. Expert Opinion on Biological Therapy, 13, 1273-85.   DOI
31 Voorhees PM, Dees EC, O'Neil B, Orlowski RZ (2003). The proteasome as a target for cancer therapy. Clin Cancer Res, 9, 6316-25.
32 Agrawal AG, Somani RR (2011). Farnesyltransferase inhibitor sin cancer treatment. In 'Current Cancer Treatment - Novel Beyond Conventional Approaches', Ed. Ozdemir O. InTech, Croatia, pp149-172.
33 Voorhees PM, Orlowski RZ (2006). The proteasome and proteasome inhibitors in cancer therapy. Ann Rev Pharmacol Toxicol, 46, 189-213.   DOI
34 Wu HC, Huang CT, Chang DK (2008). Anti-angiogenic therapeutic drugs for treatment of human cancer. J Cancer Molecules, 4, 37-45.
35 Zheng L, Li J, Luo Y (2012). Glucose metabolism and cancer. In 'Biochemistry', Ed. Ekinci D. InTech, Croatia, pp 289-304.
36 Abdalla MY (2011). Glutathione as potential target for cancer therapy; more or less is good? Jordan J Biol Sci, 4, 119-24.
37 Advani SH (2010). Targeting mTOR pathway: a new concept in cancer therapy. Indian J Med Paediatr Oncol, 31, 132-6.
38 Bolden JE, Peart MJ, Johnstone RW (2006). Anticancer activities of histone deacetylase inhibitors. Nature Rev Drug Discovery, 5, 769-84.   DOI   ScienceOn
39 Aqeilan RI, Zanesi N, Croce CM (2009). Environmental, genetic, and viral causes of cancer. In 'The biology and treatment of cancer', Eds. Pardee AB, Stein GS. John Wiley & Sons, Inc, New Jersey, pp 35-56.
40 Arora A, Scholar EM (2005). Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther, 315, 971-9.   DOI   ScienceOn
41 Blagden S, Bono JD (2005). Drugging cell cycle kinases in cancer therapy. Curr Drug Targets, 6, 325-35.   DOI
42 Canavese M, Santo L, Raje N (2012). Cyclin dependent kinases in cancer: Potential for therapeutic intervention. Cancer Biol Ther, 13, 451-7.   DOI
43 Cetin I, Topcul M (2012). Cancer stem cells in oncology. J BUON, 17, 644-8.
44 Chumsri S, Howes T, Bao T, Sabnis G, Brodie A (2011). Aromatase, aromatase inhibitors, and breast cancer. J Steroid Biochem Mol Biol, 125, 13-22.   DOI
45 Chauhan D, Hideshima T, Mitsiades C, Richardson P, Anderson KC (2005). Proteasome inhibitor therapy in multiple myeloma. Mol Cancer Ther, 4, 686-92.
46 Cheetham GM (2004). Novel protein kinases and molecular mechanisms of autoinhibition. Curr Opin Struct Biol, 14, 700-5.   DOI   ScienceOn
47 Cheng L, Zhang S, Davidson DD, Montironi R, Lopez-Beltran A (2009). Implications of cancer stem cells for cancer therapy. In 'Cancer drug discovery and development', Eds. Bagley RG, Teicher BA. Humana Press, USA, pp 255-262.
48 Duan D, Li SL, Zhu YQ, et al (2012). Radioimmunoimaging with mixed monoclonal antibodies of nude mice bearing human lung adenocarcinoma xenografts. Asian Pac J Cancer Prev, 13, 4255-61.   과학기술학회마을   DOI
49 Clemens JA, Bennett DR, Black LJ, Jones CD (1983). Effects of a new anti-estrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin secretion. Life Sci, 32, 2869-75.   DOI
50 Diaz-Padilla I, Siu LL, Duran I (2009). Cyclin-dependent kinase inhibitors as potential targeted anticancer agents. Investigational New Drugs, 27, 586-94.   DOI
51 Foreman KE, Rizzo P, Osipo C, Miele L (2009). The cancer stem cell hypothesis. In 'Cancer drug discovery and development', Eds. Bagley RG, Teicher BA. Humana Press, USA, pp 3-14.
52 Gryder BE, Sodji QH, Oyelere AK (2012). Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Future Medicinal Chemistry, 4, 505-24.   DOI
53 Gao XH, Yang XQ, Wang BC, Liu SP, Wang FB (2013). Overexpression of twist and matrix metalloproteinase-9 with metastasis and prognosis in gastric cancer. Asian Pac J Cancer Prev, 14, 5055-60.   과학기술학회마을   DOI   ScienceOn
54 Genin E, Reboud-Ravaux M, Vidal J (2010). Proteasome inhibitors: recent advances and new perspectives in medicinal chemistry. Current Topics in Medicinal Chemistry, 10, 232-56.   DOI
55 Gollob JA, Wilhelm S, Carter C, Kelley SL (2006). Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Seminars in Oncology, 33, 392-406.   DOI   ScienceOn
56 Guo YT, Hou QY, Wang N (2011). Monoclonal antibodies in cancer therapy. Clin Oncol Cancer Res, 8, 215-9.   DOI
57 Hejmadi M (2009). How cancer arises? In 'Introduction to cancer biology', Ed. Hejmadi M. Ventus Publishing ApS, United Kingdom, pp 6-12.
58 Gupta S, Singh RP, Rabadia N, Patel G, Panchal H (2011). Antisense technology. Int J Pharmaceutical Sci Review and Res, 9, 38-45.
59 Hamanaka RB, Chandel NS (2012). Targeting glucose metabolism for cancer therapy. J Exp Med, 209, 211-5.   DOI
60 Hebert JR (2009). Epidemiology: identifying cancer's causes. In 'The biology and treatment of cancer', Eds. Pardee AB, Stein GS. John Wiley & Sons Inc, New Jersey, pp 223-255.
61 Johnston SRD (2001). Farnesyl transferase inhibitors: a novel targeted therapy for cancer. Lancet Oncol, 2, 18-26.   DOI
62 Howell A (2012). Genesis and outcome of a breast cancer trial to develop the aromatase inhibitor anastrozole. Clin Chem, 58, 782-3.   DOI
63 Hurwitz HI (2004). Introduction: targeting angiogenesis in cancer therapy. The Oncologist, 9, 1.
64 Jensen EV, Jordan VC (2003). The estrogen receptor: a model for molecular medicine. Clin Cancer Res, 9, 1980-9.
65 Jones NP, Schulze A (2012). Targeting cancer metabolism-aiming at a tumour's sweet-spot. Drug Discov Today, 17, 232-41.   DOI
66 Jordan VC, Collins MM, Rowsby L, Prestwich G (1977). A monohydroxylated metabolite of tamoxifen with potent antioestrogen activity. J Endocrinol, 75, 305-16.   DOI   ScienceOn
67 Karamysheva AF (2008). Mechanisms of angiogenesis. Biochem, 73, 751-62.
68 Lindahl T, Satoh MS, Poirier GG, Klungland A (1995). Post-translational modification of poly(ADP-ribose)polymerase induced by DNA strand breaks. Trends Biochem Sci, 20, 405-12.   DOI
69 Knockaert M, Greengard P, Meije L (2002). Pharmacological inhibitors of cyclin-dependent kinases. Trends in Pharmacoll Sci, 23, 417-25.   DOI   ScienceOn
70 Kondapalli L, Soltani K, Lacouture ME (2005). The promise of molecular targeted therapies: protein kinase inhibitors in the treatment of cutaneous malignancies. J Am Acad Dermatol, 53, 291-302.   DOI
71 Massova I, Kotra LP, Fridman R, Mobashery S (1998). Matrix metalloproteinases: structures, evolution, and diversification. FASEB J, 12, 1075-95.
72 Kushner DM, Silverman RH (2000). Antisense cancer therapy: the state of the science. Curr Oncol Reports, 2, 23-30.   DOI
73 Liu Z, Wang L, Zhang LN, et al (2012). Expression and clinical significance of mTOR in surgically resected non-small cell lung cancer tissues: a case control study. Asian Pac J Cancer Prev, 13, 6139-44.   과학기술학회마을   DOI
74 London CA (2012). Tyrosine kinase inhibitors in veterinary medicine. Top Companion Anim Mede, 24, 106-12.
75 Meiyanto E, Hermawan A, Anindyajati (2012). Natural products for cancer-targeted therapy: citrus flavonoids as potent chemopreventive agents. Asian Pac J Cancer Prev, 13, 427-36.   과학기술학회마을   DOI   ScienceOn
76 Mukanganyama S, Widersten M, Naik YS, et al (2002). Inhibition of glutathione S-transferases by antimalarial drugs possible implications for circumventing anticancer drug resistance. Int J Cancer, 97, 700-5.   DOI
77 Pan JB, Hou YH, Zhang GJ (2013). Correlation between EGFR mutations and serum tumor markers in lung adenocarcinoma patients. Asian Pac J Cancer Prev, 14, 695-700.   과학기술학회마을   DOI   ScienceOn
78 Narashimamurthy J, Rao AR, Sastry GN (2004). Aromatase inhibitors: a new paradigm in breast cancer treatment. Curr Med Chem Anticancer Agents, 4, 523-34.   DOI
79 Nguewa PA, Fuertes MA, Alonso C, Perez JM (2003). Pharmacological modulation of poly (ADP-ribose) polymerase- mediated cell death: exploitation in cancer chemotherapy. Mol Pharmacol, 64, 1007-14.   DOI
80 Posada JG, Frankel AE (2008). Monoclonal antibody therapy of cancer. In 'The molecular basis of cancer', Eds. Mendelsohn AC, Howley A, Israel S, Gray JE, Lindsten T. Elsevier, Philadelphia, pp 671-678.
81 D'Amours D, Desnoyers S, D'Silva I, Poirier GG (1999). Poly (ADPribosyl) ation reactions in the regulation of nuclear functions. Biochem J, 342, 249-68.   DOI   ScienceOn
82 Hidalgo M, Eckhardt SG (2001). Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst, 93, 178-93.   DOI   ScienceOn
83 Yuan R, Kay A, Berg WJ, Lebwohl D (2009). Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol, 2, 1-12.   DOI   ScienceOn
84 Tu Y, Chen C, Pan J, et al (2012). The ubiquitin proteasome pathway (UPP) in the regulation of cell cycle control and DNA damage repair and its implication in tumorigenesis. Int J Clin Exp Pathol, 5, 726-38.
85 Carter G, Lemoine NR (1993). Antisense technology for cancer therapy: does it make sense? Br J Cancer, 67, 869-76.   DOI
86 Alanazi M, Pathan AAK, Shaik JP, Amri AA, Parine NR (2013). The C allele of a synonymous SNP (rs1805414, Ala284Ala) in PARP1 is a risk factor for susceptibility to breast cancer in Saudi patients. Asian Pac J Cancer Prev, 14, 3051-6.   과학기술학회마을   DOI   ScienceOn
87 Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002). The protein kinase complement of the human genome. Science, 298, 1912-34.   DOI   ScienceOn